Janney Capital Management LLC Invests $290,000 in Structure Therapeutics Inc. (NASDAQ:GPCR)

Janney Capital Management LLC purchased a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 6,602 shares of the company’s stock, valued at approximately $290,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GPCR. FORA Capital LLC acquired a new position in shares of Structure Therapeutics in the 1st quarter worth approximately $732,000. Capital International Investors grew its holdings in shares of Structure Therapeutics by 50.8% during the first quarter. Capital International Investors now owns 1,281,564 shares of the company’s stock worth $54,928,000 after purchasing an additional 431,540 shares during the last quarter. Capital Research Global Investors increased its stake in shares of Structure Therapeutics by 56.9% in the first quarter. Capital Research Global Investors now owns 1,527,483 shares of the company’s stock valued at $65,468,000 after buying an additional 553,948 shares in the last quarter. Altitude Crest Partners Inc. acquired a new position in Structure Therapeutics during the 1st quarter worth about $8,793,000. Finally, Bellevue Group AG grew its holdings in Structure Therapeutics by 2,858.7% during the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after acquiring an additional 351,626 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. JMP Securities decreased their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $86.80.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $41.14 on Monday. The firm has a fifty day moving average of $39.57 and a two-hundred day moving average of $39.79. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of -54.85 and a beta of -3.22. Structure Therapeutics Inc. has a 52 week low of $26.61 and a 52 week high of $74.21.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, research analysts forecast that Structure Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.